ALTERITY THERAPEUTICS LTD (ATHE) Form 6-K — Oct 9, 2026
Alterity Therapeutics announced that CEO David Stamler, M.D. will present at the Canaccord Genuity Drug and Device Conference on October 12, 2026, delivering a corporate presentation and hosting investor roundtables. The company remains focused on disease-modifying therapies for Multiple System Atrophy and related Parkinsonian disorders, and is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434 in MSA.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.